by Truveta Research | Jul 10, 2023 | Research, Research Insights
We explored the demographic characteristics of patients with type 2 diabetes mellitus, heart failure, and chronic kidney disease who received a prescription for empagliflozin (Jardiance) and/or dapagliflozin (Farxiga), two commonly used SGLT2i drugs. We saw...
by Truveta staff | Feb 15, 2023 | News, Research
The United States is one of the most dangerous high-income countries in which to give birth. Nearly every negative maternal health outcome impacts women of color more than white women. This February, in honor of Heart Health Month and Black History Month, Truveta...
by Truveta Research | Feb 7, 2023 | Research, Research Insights
Among women with preeclampsia, new Truveta Research findings show that Black women are two times more likely to experience heart failure than white women. Maternal health outcomes in the US are worse than in many other high-income countries such as England, France,...
